Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | EED | O75530 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958152 | 0.85 | TSHR (0.54) | CYP19A1TSHRGAAPKMSMN1; SMN2 | |
| SCHEMBL2146048 | 0.85 | PKM (0.64) | TSHRGAAPKMSMN1; SMN2 | |
| SCHEMBL2145110 | 0.84 | TSHR (0.52) | CYP19A1TSHRGAAPKMSMN1; SMN2 | |
| SCHEMBL1753177 | 0.83 | MAPK1 (0.55) | CYP19A1TSHRGAAPKMSMN1; SMN2 | |
| SCHEMBL2146040 | 0.80 | RECQL (0.42) | TSHRGAAPKMSMN1; SMN2RECQL | |
| SCHEMBL11213556 | 0.77 | SMN1; SMN2 (0.55) | CYP19A1TSHRGAAPKMSMN1; SMN2 | |
| SCHEMBL17456271 | 0.75 | SMN1; SMN2 (0.53) | CYP19A1TSHRGAAPKMSMN1; SMN2 | |
| SCHEMBL1753091 | 0.75 | SMN1; SMN2 (0.53) | CYP19A1TSHRGAAPKMSMN1; SMN2 | |
| SCHEMBL20477328 | 0.75 | CYP19A1 (0.55) | CYP19A1TSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7086563 | 0.75 | CYP19A1 (0.43) | CYP19A1TSHRGAAPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040702-B1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | claimed |
| US-8329738-B2 | Use of AMPK-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-12-11 | — | — | US | disclosed |
| EP-2040702-B1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| EP-2040702-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Merck Patent GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006432-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PRKAG1, PRKAB1, PRKAG2 | CYP19A1 527/4885TSHR 2382/4885GAA 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.